Market closedNon-fractional

Dynavax/DVAX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Dynavax

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Ticker

DVAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

EmeryVille, United States

Employees

408

Dynavax Metrics

BasicAdvanced
$1.5B
Market cap
163.65
P/E ratio
$0.07
EPS
1.19
Beta
-
Dividend rate
$1.5B
1.19
15.201
13.783
40.671
41.408
-3.13%
-1.35%
1.56%
163.65
6.07
2.34
2.34
27.19
-63.98%
-95.89%
27.98%
-51.01%

What the Analysts think about Dynavax

Analyst Ratings

Majority rating from 5 analysts.
Buy

Dynavax Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-17.15% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$51M
-8.65%
Net income
-$8.7M
-4,450.00%
Profit margin
-17.15%
-4,863.89%

Dynavax Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 211.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.03
$0.10
-
-$0.07
-
Expected
-$0.09
-$0.02
-$0.01
-$0.02
$0.07
Surprise
-132.70%
-766.67%
-
211.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Dynavax stock?

Dynavax (DVAX) has a market cap of $1.5B as of July 05, 2024.

What is the P/E ratio for Dynavax stock?

The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 163.65 as of July 05, 2024.

Does Dynavax stock pay dividends?

No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Dynavax dividend payment date?

Dynavax (DVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Dynavax?

Dynavax (DVAX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Dynavax stock

Buy or sell Dynavax stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing